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INTRODUCTION
Tuberous sclerosis (TS) is a relatively
common autosomal dominant genetic
disorder due to defects in hamartin (tsc1)
and/or tuberin (tsc2) (1–5). TS is notable
for the development of benign neo-
plasms of the kidney, lungs, brain, and
skin, as well as cortical tubers (2,6). Cor-
tical tubers are giant cells that express
neuronal and glial markers (7,8). While
seizures remain the leading cause of
morbidity and mortality in children, im-
provements in neurological care are lead-
ing to an increased population of adults
with TS. The leading cause of morbidity
and mortality in adults with TS are kid-
ney tumors. Kidney tumors in adults
with TS are overwhelmingly angiomy-
olipomas, a tumor which histologically
expresses cells with smooth muscle, fat,
and melanocytic markers (9). Previous
studies of angiomyolipomas presumed
that these were hamartomas, given the
mixture of cell types, but more recent
studies have shown that these lesions are
clonal, thus representing true neoplasms
(10,11). Supporting this concept, loss of
heterozygosity of tsc1 or tsc2 is com-
monly observed in angiomyolipomas
from patients with TS, and in a lower fre-
quency in sporadic angiomyolipomas
(12,13). Currently angiomyolipomas are
thought to derive from perivascular ep-
ithelioid cells, a cell type of which no
normal counterpart is known.
The histogenesis of angiomyolipoma is
unknown, and there are no known cells
in the normal adult vertebrate that con-
sistently express both smooth muscle
and melanocytic genes. However, recent
studies have shown that neural crest
cells can give rise to smooth muscle cells,
as well as melanocytes, and that, in the
mouse, multipotent stem cells can be iso-
lated that can differentiate into either
melanocytes or smooth muscle cells, de-
pending on the culture condition. These
precursor cells express the cell surface
markers NG2 and L1 (14–18). In order to
determine whether angiomyolipomas
may represent the human equivalent of
precursor cells to melanocytes/smooth
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muscle, we stained angiomyolipoma
cells with NG2 and L1 antisera, and
found strong expression in angiomy-
olipoma in vivo, but not in conventional
renal cell carcinoma. These findings sug-
gest that angiomyolipomas may arise
from a disturbance in differentiation of
stem cells. We also found that angio-
myolipoma expresses members of the
microphthalmia (MITF/TFE3/TFEB)
family of transcription factors, suggest-
ing that angiomyolipoma may share a
common neural crest origin with
melanoma, pediatric renal cell carcino-
mas, and alveolar soft part sarcoma,
which also express these transcription
factors.
MATERIALS AND METHODS
Immunofluorescence
Live SV7tert human angiomyolipoma
cells (18,19) were immunostained using a
30 min incubation at room temperature
with primary antibodies diluted in
DMEM containing 2% fetal calf serum.
After three washes with DMEM/FCS,
cells were incubated with secondary an-
tibodies for an additional 30 min. Fol-
lowing three more washes, cells were
fixed for 1 min with cold 95% ethanol,
air dried, and coverslipped in Immu-
mount (Shandon, Pittsburg, PA, USA).
Specimens were examined using a Nikon
Optiphot microscope equipped for epi-
fluorescence.
Samples
Fresh frozen tissue sections of two
renal AMLs and one renal cell carcinoma
were obtained from files at the Depart-
ment of Pathology of Emory University
Hospital. All samples were collected
under protocols approved by the institu-
tional review board (IRB)(Emory IRB
number: 255-2002). Fresh tissues were im-
mediately embedded in Tissue Tek OCT
medium (Thermo Shandon, Pittsburgh,
PA, USA), snap-frozen in liquid nitrogen,
and stored at –80° C until use. Frozen
sections were cut and placed on commer-
cially-provided charged slides (Fisher Sci-
entific, Pittsburgh, PA, USA), at 5 μm
with a cryostat and immediately fixed in
acetone for 10 min. After complete dehy-
dration by air drying, samples were kept
in a –20° C deep freezer until use.
Cell lines
An angiomyolipoma cell line,
UMBSVtel, was established from an
angiomyolipoma surgically removed
from a tuberous sclerosis patient. The
cells were sequentially transfected with
SV40 large T antigen and then infected
with telomerase as previously described
(18). The SV7tert cell line was derived
from a spontaneous angiomyolipoma.
Sequencing for mutations was performed
as previously described (19).
Antibodies
Three anti-human NG2 monoclonal
antibodies were used for immunohisto-
chemistry. The B5 hybridoma (20) was
obtained from American Type Culture
Collection. 9.2.27 (purified IgG; Chemi-
con) and N143.8 (ascites fluid (14)) have
been described previously (14). The F84.1
monoclonal antibody (21) and rabbit
anti-L1 antibody (RaL1/EC aff) (22) have
been described previously. F84.1 is an an-
tibody directed against DM-GRASP, an
antigen found on both neural and
hematopoetic stem cells (23). Table 1 in-
dicates the summary of known charac-
teristics of the epitopes for those antibod-
ies. The specificity of all antibodies has
been confirmed by Western blot.
Immunohistochemistry
After removal from the –20° C deep
freezer, the slides were washed in TBS
buffer. Then the tissue sections were in-
cubated for 15 min with the following
primary antibodies: the B5 hybridoma at
the dilution of 1:16; the 9.2.27 at the dilu-
tion of 1:4,000; the N143.8 at the dilution
of 1:800; the F84.1 at the dilution of 1:16,
and rabbit anti-L1 antibody (RaL1/EC
aff) at the dilution of 1:800. Table 1 indi-
cates the summary of known characteris-
tics of the epitopes for those antibodies.
The specificity of all antibodies has been
confirmed by the Western blot method.
After washing the unbound primary
antibodies, sections were treated with
commercial biotinylated secondary anti-
immunoglobulin followed by avidin cou-
pled to biotinylated horseradish peroxi-
dase, according to manufacturer’s
instructions (LSAB2 kit for mouse and
rabbit primary antibodies, DAKO Corp.,
Carpinteria, CA, USA).
Diaminobenzidine was used as the
chromogenic peroxidase substrate for
five minutes, and sections were counter-
stained with hematoxylin for 15 min
after immunohistochemistry. These incu-
bations were performed using automated
immunostainer (DAKO). Specificity of
the procedure was verified by negative
control reactions with primary antibody
replaced with buffer.
Cell pellets from SV7Tert and UMBSV-
tel cells were lysed in running buffer
(40 mM HEPES, 100 mM KCl, 40% glyc-
erol, 2 mM β-mercaptoethanol, 0.5% NP-
40) and sonicated. 20 µg of protein sam-
ple was separated on a 10% acrylamide
Bis/Tris gel and protein expression was
analyzed by Western Blotting (Western
Breeze, Invitrogen, Carlsbad, CA. USA)
using PAX3 rabbit polyclonal antibody 
(J Li et al, (1999) Development 126:
2495-2503) (25).
RNA was isolated from SV7Tert cells
using Trizol reagent (Sigma, St. Louis,
MO, USA). After generation of cDNA
(Superscript, Invitrogen) transcripts were
amplified by polymerase chain reaction
using primers for PAX3 (ATA GTG GAG
ATG GCC CAC CA and CTC CTC AGG
ATG CGG CTG AT) and GAPDH (AGT
GGG TGT CGC TGT TGA AGT and TGC
CAA ATA TGA TGA CAT CAA GAA).
RT-PCR for TFE3, TFEB, TFEC
Total RNA was purified from SV7tert,
UMBSVtel, or control (501mel, EWS502)
cell lines with TRIzol reagent (Invitrogen)
as recommended by the manufacturer.
Five μg RNA was reverse transcribed
after oligo (dT)16 priming with Super-
script III (Invitrogen) as recommended by
the manufacturer. cDNA was amplified
by PCR with primers specific for TFE3
(5′-GCAGGCGATTCAACATTAACG-3′,
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5′-ATAATCCACAGAGGCCTTCAG-3′),
TFEB (5′-GGGAGTTGGATGATGT-
CATTG-3′, 5′-GGCATCTGCATTTCA
GGATTG-3), TFEC (5′-GGACAACCACA
ACCTCATTGA-3′, 5′-CCAGCGCATATC
AGGATCATT-3′) or GAPDH (5′-GAAG
GTGAAGGTCGGAGT-3′, 5′-GAAGATG
GTGATGGGATTTC-3′) mRNA using Taq
DNA polymerase repeating 35 cycles of
94 °C for 30 s, 54 °C for 30 s and 72 °C
for 30 s. PCR products were separated by
agarose gel electrophoresis.
RESULTS
Tables 1 and 2 and Figure 1 summa-
rized the specificities for and the results of
immunostaining for these antibodies. Ex-
pression of three NG2 antibodies includ-
ing B5 hybridoma, 9.2.27, and N143.8 was
consistently positive in renal AML, but
negative in RCC (Figure 2). Blood vessel
walls were also positive for these NG2 an-
tibodies. Expression of F84.1 antibody
was positive in RCC and AML as well as
blood vessels (data not shown). Expres-
sion of RaL1/EC aff, which recognizes the
neural crest marker L1 was positive in
AML but negative in RCC (Figure 3). En-
dothelial cells were faintly stained for
RaL1/EC aff but vascular wall was nega-
tive (Figure 3).
Angiomyolipoma cells did not express
the pre-migratory neural crest gene pax3
at the level of RNA (data not shown).
This is consistent with angiomyolipoma
being a postmigratory phenotype.
Angiomyolipoma cells express high lev-
els of TFE3 RNA (Figure 4), but an-
giomyolipomas do not express TFE3 by
immunohistochemistry, consistent with a
translational block (data not shown).
Both SV7tert and UMBSVtel cells stained
positively for NG2. We found a deletion
mutation in UMBSVtel cells “4083-4087
del AGTCG” in exon 33 of the TSC2
gene. This cell line represents the first
cell line derived from an angiomy-
olipoma cell with a defined mutation in
tuberin, making it valuable for studies of
tuberous sclerosis. The pattern of TFE
family RNA expression in UMBSVtel
cells is nearly identical to that of SV7tert
(data not shown).
DISCUSSION
Angiomyolipomas are tumors that
show histologic evidence of smooth mus-
cle, fat, and melanocytic markers. While
these tumors are histologically benign,
they are the major cause of morbidity
and mortality in adults with tuberous
sclerosis. Angiomyolipomas are notori-
ously susceptible to rapid hemorrhage,
and multiple angiomyolipomas may
obliterate the renal parenchyma, causing
renal failure, and the need for renal
transplantation. Currently, the only treat-
ments for angiomyolipomas are excision
or embolization.
Most of the neoplasms and hamar-
tomas of tuberous sclerosis exhibit multi-
lineage phenotypes. Cortical tubers of
Table 1. Antibodies to Neural Crest Antigens
Antibody Source Type Dilution
B5 American Type Culture Collection monoclonal 1:16
9.2.27 Chemicon monoclonal 1:4,000
N143.8 Stallcup monoclonal 1:800
F84.1 Stallcup monoclonal 1:16
RaL1/EC aff Stallcup polyclonal 1:800
Table 2. Summary of staining results
Antibody AML RCC BVW
B5 positive negative positive
9.2.27 positive negative positive
N143.8 positive negative positive
F84.1 positive positive positive
RaL1/EC aff positive negative negative
BVW, blood vessel wall; EC, endothelial cells.
Figure 1. Immunocytochemistry for NG2 and L1 on SV7tert angiomyolipoma cells. A) Liv-
ing SV7tert cells were labeled with B5 mouse monoclonal antibody against human NG2.
All cells were found to be NG2-positive. (B,C). Living SV7tert cells were double-stained for
F84.1 (B) and L1 (C). All cells expressed F84.1, a cell adhesion molecule that is wide-
spread during embryonic development. However, only a subpopulation of cells is positive
for the L1 cell adhesion molecule, which is expressed by neural crest. Bar in C = 20 μm.
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tuberous sclerosis, the major cause of
seizures in affected children, exhibit a
combined neuronal-glial phenotype. Col-
lagenomas exhibit a mixed population of
fat, smooth muscle, and collagen deposi-
tion. Lymphangiomyomatosis, which
may cause respiratory failure, exhibits a
similar phenotype of smooth muscle and
melanocytic lesions to angiomyolipoma.
This clinical finding of multilineage phe-
notypes suggests that the signaling aber-
rations in tuberous sclerosis result from a
perturbation of stem cell differentiation.
Smooth muscle cells arise from endo-
derm and neural crest. Specifically, a
common neural crest precursor can dif-
ferentiate into glia, smooth muscle, peri-
cytes, cartilage, myofibroblast, and neu-
rons. Platelet derived growth factor α
(PDGFα) and pax family transcription
factors are required for initial prolifera-
tion of neural crest stem cells, which mi-
grate to peripheral tissues. Pax genes are
expressed in neural crest prior to migra-
tion to the periphery, and the lack of
pax3 expression in SV7tert angiomy-
olipoma cells is consistent with the
known patterns of pax expression (24).
Maintenance and differentiation of these
stem cell derivatives occurs through lo-
cally based trophic factors, such as
platelet-derived growth factor α
(PDGFα). Angiogenic vascular endothe-
lium produces abundant PDGF-BB, and
deficiency of PDGF-BB in knockout mice
results in severe kidney defects due to
the presence of angiogenic endothelium
not being invested by smooth muscle
and pericytes (19,25). Of interest, an-
giomyolipoma cells express high levels
of PDGF-BB, and proliferation of an-
giomyolipoma cells in vitro is inhibited
by PDGFRb tyrosine kinase antagonists,
including glivec. Activated (phosphory-
lated) PDGFRb is expressed in angiomy-
olipoma tumor tissue, indicating patho-
physiologic activation of PDGF-BB/
PDGFRβ in vivo (26).
Neural crest contributes to the devel-
opment of the embryonic kidney.
Neural crest cells expressing the L1 neu-
ral cell adhesion protein are present in
the embryonic metanephric kidney rudi-
ment, and their proliferation is en-
hanced by neurotropin 3 (NT-3) (27,28).
Of interest, a population of SV7tert cells
and angiomyolipoma tumors express L1
in addition to NG2, supporting a neural
crest origin for angiomyolipoma cells.
NG2 also may play a role in mainte-
nance of these tumors, as NG2 has been
shown to sequester and inactivate an-
giostatin, thus permitting pathologic an-
giogenesis (29).
Angiomyolipomas are the most com-
mon kidney neoplasms that express
melanocytic markers. In melanocytes,
MITF is the major transcriptional switch
for the distinct metabolic pathways for
melanin formation, but MITF appears to
have antiapoptotic and oncogenic func-
tions independent of this. MITF shares
biochemical similarity to the TFE3/TFEB
transcription factors, and this extends to
protection against apoptosis and oncoge-
Figure 2. Renal angiomyolipomas, but not renal cell carcinomas, express NG2 in vivo.
Renal AML with thick walled blood vessel associated with typical component of smooth
muscle cells and normal appearing fat cell was positive for B5 (Figure 2A), 9.2.27
(Figure 2C), and N143.8 (Figure 2E), but RCC tumor cells were negative for those anti-
bodies (Figure 2B, 2D, and 2F). Blood vessels were positive for these antibodies.
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nesis (30,31). Previous mechanisms for
activation of these transcription factors
include translocation, which occurs in a
subset of pediatric renal cell carcinomas
and alveolar soft part sarcomas (19,32).
In addition, these factors are expressed
in Ewing’s sarcoma through transcrip-
tional activation. Our data suggests that
angiomyolipoma, which is far more com-
mon than pediatric renal cell carcinoma,
alveolar soft part sarcoma, and Ewing’s
sarcoma, may arise from a similar neural
crest precursor. Angiomyolipoma cells
are sensitive to blockade of PDGFRβ,
and pharmacologic blockade of PDGFRβ
activation with drugs such as glivec, may
be useful in the treatment of angiomy-
olipoma (36). In addition, angiogenesis
inhibition may serve to deprive angio-
myolipoma cells of trophic PDGF-BB
production, and avastin, a VEGF trap,
has been shown to be efficacious in renal
cell carcinoma. Finally, NG2 binding
peptides have been made which target
tumor vessels (34). The presence of NG2
on angiomyolipoma cells may enhance
tumor killing by peptides which bind
NG2. Thus, an understanding of the em-
bryonic basis of angiomyolipoma may be
beneficial in therapy of this common
tumor.
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